Pharmaceutical

KeyBioscience and Eli Lilly extend partnership for obesity treatments

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated disorders.

Oct 12, 2024 - 04:00
KeyBioscience and Eli Lilly extend partnership for obesity treatments
KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated disorders.
Read the original article

Tags:

Previous Article

Booster Therapeutics to develop proteasome activator medicines

Next Article

CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Inhalation Sciences and Actarmo enter respiratory drugs collaboration

Inhalation Sciences and Actarmo enter respiratory drugs...

Jan 23, 2024

FDA launches new rare disease innovation hub

FDA launches new rare disease innovation hub

Jul 20, 2024

STAT+: How UnitedHealth’s acquisition of a popular Medicare Advantage algorithm sparked internal dissent over denied care

STAT+: How UnitedHealth’s acquisition of a popular Medi...

Jul 12, 2023